[Department of Error] Department of Error
Van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017; 390: 1645–53—In the list of affiliations for this Article (published online first on Aug 8, 2017), “Prof R Stuff MD” should have read “Prof R Stupp MD”. This correction has been made to the online version as of Oct 5, 2017, and the printed Article is correct.